Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib with Chemoradiation in Esophageal/GEJ Cancer
NCT04929392Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in esophageal cancer and gastroesophageal junction cancer, sponsored by City of Hope. Primary endpoints: Pathological Complete Response at 14 weeks and Clinical Complete Response at 14 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04929392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929392.